Meet immunoSCAPE and see our data at the SITC 2018 Annual Meeting!
As a benefit for attending the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC) provides enduring materials free of charge for the specific programs attended. If you are a SITC member, or member of the general public, but did not register to attend a Pre-Conference program or the 33rd Annual Meeting, the materials are now available by clicking the links below.
Meet us at the NeoAg Summit in Boston!
The 4th annual NeoAg Summit is returning to Boston this November to provide your team with one all-inclusive forum to successfully target tumor-specific neoantigens and bring to market personalized cancer vaccines and cellular therapies.
immunoSCAPE will be at the ESMO 2018 Congress
A multi-professional platform for oncology education and exchange, and for immense international visibility for scientific research, this year the Congress featured a dedicated nursing track through a collaboration with the European Oncology Nursing Society (EONS).
immunoSCAPE will be presenting at the Advances in Immuno-Oncology USA Congress 2018
Oxford Global’s R&D US Series features 3 outstanding programmes: our long-running 5th Annual Drug Discovery and Chemistry USA Congress, the 3rd Annual Biomarkers & Precision Medicine USA Congress, and fast-emerging Advances in Immuno-Oncology USA Congress.
immunoSCAPE will be presenting at the Biomarkers & Immuno-Oncology World Congress 2018 in Boston!
The future of immuno-oncology drug development is positioned in combination therapies, where immunotherapy modalities are tested in rational combinations with other immunotherapies or targeted therapies for synergistic effects. Combination immunotherapy promises to deliver long-term survival benefits that may be unavailable with current approaches. The Second Annual Combination Immunotherapy meeting will explore the most effective combinations of immunotherapy with conventional cancer therapy, with other immunotherapy or with targeted therapy. Coverage will include understanding the mechanism of action, managing toxicity, strategies to design synergistic combinations, biomarker development and case studies of ongoing combination immunotherapy studies from the leading researchers in industry and academia.
Dr Newell to discuss his technology at the SITC workshop ‘Immuno-Oncology Biomarkers: State of the Art’
The Immuno-Oncology Biomarkers Workshop will identify the next steps for action in immunotherapy biomarker development. It will provide a forum for energetic discussion about the collaborative efforts across several societies and consortia, make progress on identification and analysis of novel biomarkers, and tackle data analysis and specimen sharing. The final session will bring together representatives from the fields of immune-oncology research, infectious disease, autoimmune disease and cell biology to discuss opportunities for cross-disciplinary collaboration to advance biomarker development.